Bellvitge Biomedical Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bellvitge Biomedical Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH292789D
  • |
  • Pages: 49
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center that offers health care development solutions. The center conducts clinical and basic research for developing treatments and techniques to improve health care. It offers its research work in the fields of neurosciences, infectious pathology and transplants, cancer and human molecular genetics, growth factors, inflammatory, chronic and degenerative diseases, hormones and diabetes, epigenetics and cancer biology. IDIBELL also conducts translational medicine research for aspects of neurosciences, biomedicine, mainly cancer, and other prevalent diseases. The center manages the research of oncology institutions, universities, and other healthcare facilities. IDIBELL is headquartered in Barcelona, Spain.

Bellvitge Biomedical Research Institute-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

Oxford Immunotec Enters into Licensing Agreement with IDIBELL 11

Minoryx Therapeutics Enters Into Licensing Agreement with Universitat de Barcelona and Institut de Investigacio Biomedica de Bellvitge 12

Minoryx Therapeutics Enters into Licensing Agreement with Bellvittge Biomedical 13

Histocell Enters Into Licensing Agreement With IDIBELL For Acute Pulmonary Diseases Patent 14

Bellvitge Biomedical Research Institute-Key Competitors 15

Bellvitge Biomedical Research Institute-Key Employees 16

Bellvitge Biomedical Research Institute-Locations And Subsidiaries 17

Head Office 17

Recent Developments 18

Legal and Regulatory 18

Mar 23, 2018: IDIBELL obtains the TECNIO certification as a public technology facilitator 18

Government and Public Interest 19

Sep 25, 2018: IDIBELL researchers receive AECC grants on World Cancer Research Day 19

Aug 11, 2018: A new epigenetic signature predicts the response to immunotherapy in lung cancer 21

Aug 01, 2018: The biochemical signature of the synapse in a model of Down syndrome is identified with high resolution 22

Jun 27, 2018: New combined treatment shows promise in Hepatocellular Carcinoma 23

Jun 11, 2018: New epigenetic drug against Mantle Cell Lymphoma 24

May 14, 2018: Scientists discover a variation of the genome predisposing to Alzheimer's disease 25

Apr 20, 2018: The EPICUP Project receives a Pfizer Foundation Innovation award 26

Apr 05, 2018: A potential new therapeutic target for Ewing sarcoma 27

Mar 15, 2018: Creation of a web platform for the identification of fronto-subcortical connectivity alterations in brain disorders 28

Feb 20, 2018: RAC1 protein could be a new therapeutic target to fight neurodegeneration in Parkinson's disease 29

Jan 31, 2018: EU empowers four IDIBELL researchers with Marie Sklodowska-Curie Individual Fellowships 31

Jan 04, 2018: IDIBELL-ICO researchers identify a new therapeutic target to fight metastasis in ovarian cancer 32

Jan 04, 2018: IDIBELL researchers-ICO identify a new therapeutic target to combat metastasis in ovarian cancer 33

Jan 02, 2018: Alex Vaquero is awarded 200,000 euros from Worldwide Cancer Research to better understand the origin of cancer 34

Dec 19, 2017: Mild obsessive-compulsive symptoms are associated with variations of cerebral anatomy in healthy children 35

Dec 18, 2017: European project EU-TRAIN to improve the results in kidney transplant receives more than six million euros 36

Nov 21, 2017: The isoforms of the HP1 protein differentially regulate the organization and structure of heterochromatin 37

Oct 09, 2017: A new genetic marker accounts for up to 1.4% of cases of hereditary colon cancer 38

Oct 03, 2017: IDIBELL scientists identify a key regulator of the acquisition of immune tolerance to tumor cells in cancer patients 39

Jan 31, 2017: European experts highlight the potential of xenografts in personalized oncology 40

Product News 41

Jun 07, 2018: First photoactive drug to fight Parkinson's disease 41

May 09, 2018: A new drug shows preclinical efficacy in Rett syndrome 43

Apr 11, 2017: First photoactive drug for pain treatments 44

Jan 11, 2018: ICO-IDIBELL researchers successfully test a new combination therapy in sarcomas 46

Jan 11, 2018: IDIBELL researchers successfully test a new combination therapy in sarcomas 47

Other Significant Developments 48

Jun 22, 2018: CRISPR-editing of a single aminoacid make a whole animal more resistant to cisplatin-based chemotherapy 48

Appendix 49

Methodology 49

About GlobalData 49

Contact Us 49

Disclaimer 49

List of Figures

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Key Facts 2

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Bellvitge Biomedical Research Institute, Deals By Therapy Area, 2012 to YTD 2018 9

Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Oxford Immunotec Enters into Licensing Agreement with IDIBELL 11

Minoryx Therapeutics Enters Into Licensing Agreement with Universitat de Barcelona and Institut de Investigacio Biomedica de Bellvitge 12

Minoryx Therapeutics Enters into Licensing Agreement with Bellvittge Biomedical 13

Histocell Enters Into Licensing Agreement With IDIBELL For Acute Pulmonary Diseases Patent 14

Bellvitge Biomedical Research Institute, Key Competitors 15

Bellvitge Biomedical Research Institute, Key Employees 16

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Bellvitge Biomedical Research Institute, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17805
Site License
USD 500 INR 35610
Corporate User License
USD 750 INR 53415

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com